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Abstract: The central nervous system (CNS) is a very challenging HIV-1 sanctuary, in which HIV-1
replication is established early on during acute infection and can persist despite potent antiretroviral
treatments. HIV-1 infected macrophages play a pivotal role acting as vehicles for HIV-1 to spread into
the brain, and can be the major contributor of an early compartmentalization. HIV-1 infection in CNS
may lead to a broad spectrum of neurological syndromes, such as dementia, mild neurocognitive
disorders, and asymptomatic impairment. These clinical manifestations are caused by the release of
neurotoxins from infected cells (mainly macrophages), and also by several HIV-1 proteins, able to
activate cell-signaling involved in the control of cellular survival and apoptosis. This review is aimed
at highlighting the virological aspects associated with the onset of neurocognitive disorders and at
addressing the novel therapeutic approaches to stop HIV-1 replication in this critical sanctuary.
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1. Introduction
The central nervous system (CNS) represents one of the most important sanctuaries for HIV-1 [1].
The productive infection of HIV-1 in this site is primarily supported by resident macrophages [2], even
if astrocytes can also be infected by HIV-1, through the blood brain barrier (BBB), which has been
demonstrated by in vitro and in vivo studies [1]. The genetic compartmentalization of viral variants
in the CNS suggest that adaptive changes occur in response to unique constraints within the brain
microenvironment, including specific target cell populations and immune selection pressures [1].
This infection status often causes neurological symptoms including cognitive and motor
dysfunction [3]. In general, this disorder is characterized by a combination of virus-related neurological
disorders and neuronal-tissue inflammation [4]. The introduction of antiretroviral therapy (ART) and
the use of drugs with great penetration of the blood-brain barrier have drastically reduced the incidence
of these complications [5–7]. However, since not all anti-HIV drugs are able to cross the blood-brain
barrier with high efficiency, a minimal viral replication still persists that causes neurocognitive
deficits [8,9]. Therefore these clinical manifestations still remain an important complication for chronic
HIV-infected patients, especially for those that belong to special settings such as children, patients
with low adherence, and late presenters [8].
Risk factors such as low CD4+ (cell count, high viral load at baseline, low CD4+ nadir,
HCV-coinfection, drug abuse, and metabolic comorbidities are also associated with a higher incidence
of HIV-neurocognitive impairment (cited in the following paragraphs) [4,10–18].
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2. Clinical Aspects and Classification of Neurological Disorders
Despite the overall improvement of outcomes in patients receiving ART, neurocognitive
impairments continue to be present. These disorders are characterized by several dysfunctions
such as decrease of attention, mood alterations, depression, psychomotor disturbs, alteration in
the extrapyramidal movements, and spasticity, and are associated with morphological profiles
characterized by atrophy, neuro-degeneration, persistent inflammation with microglial nodules,
perivascular lymphocytes cuffing, accumulation of multinucleated cells expressing HIV antigens
(probably derived from the fusion of the uninfected and infected perivascular macrophages),
demyelinization, and white matter gliosis [4,19–21].
Several diagnostic schemes have been proposed over the years for the diagnosis of HIV-associated
neurocognitive disorders (HAND). Early diagnostic guidelines emphasized the motor, psychosocial,
and behavioral symptoms [22], rather than the severity of the impairment. In 2007 and 2011, these
requirements evolved and were defined into what is now known as the Frascati Criteria [23] and
the Gisslen criteria [6]. Up to now, the Frascati criteria [23] are the most widely used nosology of
HAND and are considered the gold standard in HIV research. Its scheme identifies three severity
levels of HAND: asymptomatic neurocognitive impairments (ANI), mild neurocognitive disorders
(MND), and HIV-associated dementia (HAD). While ANI is characterized by the presence of cognitive
function impairment in at least two domains without interfering with everyday function, with no
signs of delirium or dementia, MND is characterized by a mild cognitive function impairment slightly
interfering with normal daily activation. This status could evolve toward the more serious condition
called HAD, which is markedly incompatible with normal day-by-day life [4,18,22].
3. Cells Involved in the Pathogenesis of HIV-Associated Neurocognitive Disorders
Neuronal damage is due to the interaction between HIV-1 and different cell types (Table 1).
The primary cell targets for HIV infection, in the CNS, are resident macrophages, neurons, and
astrocytes [3,24,25]. The role of macrophages is essential in the neurodegeneration process; indeed,
these cells are resistant to HIV-1 cytopathic effects and thus can sustain a viral infection for prolonged
periods of time [26–32]. In the CNS, four major types of macrophages were identified: meningeal
macrophages, macrophages of the choroid-plexus, perivascular macrophages, and microglia [33,34].
Among them, microglia and perivascular macrophages seem to have a fundamental role in neurological
damage [33]. Their role in the inflammatory process is to release viral proteins, inflammatory cytokines,
and neurotoxins, and to induce astrocyte differentiation, apoptosis, and the alteration of the normal
neurogenesis [3,35–37].
Table 1. The role of human cells in HIV-associated neurocognitive disorders.
Cell Type Infection Type Effects in the Brain a
Astrocyte Restricted
Increases BBB permeability;
Promotes the migration of monocytes into the brain;
Increases the release of intracellular Ca2+ and glutamate;
Decreases the glutamate uptake;
Increases neurotoxins production
Microglia Productive
Induces the release of viral proteins (gp120, Tat, Vpr);
Induces neurotoxins production (inflammatory mediators,
PDGF, QUIN);
Actives viral replication
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Table 1. Cont.
Cell Type Infection Type Effects in the Brain a
Neuron Restricted
Increases the release of intracellular Ca2+;
Increases caspase activation;
Increases p53 expression
Oligodendrocyte Restricted
Reduces myelin synthesis;
Increases intracellular Ca2+ levels;
Increases cellular apoptosis
Perivascular Macrophage Productive
Induces the release of viral proteins (gp120, Tat, Vpr);
Induces the neurotoxins production (inflammatory
mediators, PDGF, QUIN);
Actives viral replication
a Data on the effects of cells in the brain were based on Ref. [3,33,35,37].
Microglial resident cells play an important role in the HAND pathogenesis, contributing to the
neurodegenerative events through various mechanisms. In fact, glial cells infected by HIV are able to
release factors and toxins which cause damage in neurons and astrocytes [3,38,39].
Astrocytes are neuroectodermal-derived cells, important components of the blood–brain-barrier,
which support the function and metabolism of neurons, the ionic homeostasis into the CNS, scar
formation, control the state of the neuronal synapses by the uptake of neurotransmitters, and tissue
repair. They also regulate the immune response in the brain [40–42]. Furthermore, astrocytes can
support low level replication of HIV, allowing the virus to persist in the central nervous system [43],
to establish a latent infection.
Moreover, in vitro studies have shown that viral factors may induce, in HIV-infected cells, the
release of other chemo-attractive factors that recruit monocytes and microglia, thus amplifying the
neuronal damage [26,44,45]. Additionally, several cellular factors such as IL-1β, TNF-α, or IFN-γ are
able to stimulate and reactivate viral replication in latently infected-cells [2,46,47].
4. The role of HIV-1 in Neuronal Damage
4.1. The Direct Mechanisms
HIV-1 is able to cross the BBB through three different mechanisms, thereby infecting the CNS
(Figure 1). The mechanisms exploited by the virus are the following:
(1) HIV-1 can directly infect endothelial cells, expressing the chemokine receptors involved in HIV-1
entry (CXCR4, CCR3, DC-SIGN) [43,48].
(2) In case of increased permeability due to other dysfunctions and/or altered tissue, the virus may
directly enter the BBB [2,49].
(3) In the “Trojan horse” hypothesis, HIV-1 infected-monocytes, leukocytes, and perivascular
macrophages crossing the BBB could release viral particles able to infect resident cells like
microglia, thus contributing to establishing a persistent infection. This mechanism has also been
observed with other retroviruses and lentiviruses and it is probably the main mechanism for HIV
penetration into the brain [43]. Several observations suggest that monocytes may be infected
before leaving the bone marrow [50]. In particular, an amount of proviral DNA was found in
these cells without the expression of viral proteins, thus allowing the dissemination of the HIV-1
infection [50,51]. A relevant role is played by a subset of monocytes (CD14lowCD16high) which
tends to increase during HIV-1 infection [34,52–56]. These cells show intermediate characteristics
between the monocytes and differentiated cells (macrophage and dendritic cells) [53,55]. They
are more permissive to HIV replication, probably due to the lower activity of the host restriction
factors than the CD14highCD16low cells [51,56], and they can more easily cross the BBB [52–54].
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Figure 1. The main characteristics of HIV infection into the CNS. (1) The different ways of HIV-1 entry 
in the CNS: (1a) the “Trojan horse” mechanism, through HIV-1 infected monocytes that cross the BBB 
and differentiate into perivascular macrophage; (1b) direct entry, possible in the case of increased 
permeability due to dysfunctions and/or altered tissue; (1c) the migration into the brain of HIV-1 
infected CD4+ T cells. (2) CNS resident cells susceptible to HIV-1 infection are microglia, neurons, 
astrocytes, and oligodendrocytes. The activation of these cells plays a key role in the release of 
proinflammatory cytokines, and can amplify the alteration and permeability of the BBB, thus 
promoting the neuroinvasion of HIV and other viruses.  
4.2. The Indirect Mechanisms 
HIV-associated neurologic disorders and neuroinflammation could also depend on three events:  
(1) the infiltration of infected monocytes and lymphocytes in the CNS;  
(2) the release of viral and cellular factors from these infected cells;  
(3) the infection of resident cells by viral particles infiltrating into the CNS or released from infected 
cells [60]. 
Cells, such as monocytes and T cells, infected with HIV, have a key role in the release of pro-
inflammatory cytokines such as TNF-α and IL-1B, which in turn activate astrocytes and microglia. 
This cellular activation, in association with perivascular macrophages, is involved in the process of 
release of neurotoxic factors, such as inflammatory mediators, platelet-derived growth factor (PDGF), 
nitrogen oxide, and quinolinic acid (QUIN). This leads to dysfunction and neuronal death [2,61]. 
A previous study has shown that despite effective antiretroviral treatment, cytokines such as 
CCL2, IL-8, CCL3, CXCL10, IFN-γ, and IL-6 were expressed at higher levels in HIV-1 infected 
patients with respect to uninfected ones. The higher expression of such cytokines indicates a 
continuous neuronal inflammation which in turn promotes HAND-associated encephalopathy [1]. 
Accordingly, Vera and his group have also recently shown the presence of neuroinflammation 
markers in neuro-asymptomatic HIV-infected patients (despite the effective control of viraemia) [62]. 
This status is probably related to the impressive microbial translocation from the gut to the 
Figure 1. The main characteristics of HIV infection into the CNS. (1) The different ways of HIV-1
entry in the CNS: (1a) the “Trojan horse” mechanism, through HIV-1 infected monocytes that cross
the BBB and differentiate into perivascular macrophage; (1b) direct entry, possible in the case of
increased permeability due to dysfunctions and/or altered tissue; (1c) the migration into the brain
of HIV-1 infected CD4+ T cells. (2) CNS resident cells susceptible to HIV-1 infection are microglia,
neurons, astrocytes, and oligodendrocytes. The activation of these cells plays a key role in the release of
proinflammatory cytokines, and can amplify the alteration and permeability of the BBB, thus promoting
the neuroinvasion of HIV and other viruses.
Moreover, the release of different viral proteins into the central nervous system could amplify
the alteration and permeability of the BBB [57,58] by inducing apoptosis [58,59] and increasing the
neuroinvasion of HIV and other viruses [2].
4.2. The Indirect Mechanisms
HIV-associated neurologic disorders and neuroinflammation could also depend on three events:
(1) the infi tr tion of infected monocytes and lymphocytes in t e CNS;
(2) the release of viral and cellular factors from these infected cells;
(3) the infection of resident cells by viral particles infiltrating into the CNS or released from infected
cells [60].
Cells, such as monocytes and T cells, infected with HIV, have a key role in the release of
pro-inflammatory cytokines such as TNF-α and IL-1B, which in turn activate astrocytes and microglia.
This cellular activation, in association with perivascular macrophages, is involved in the process of
release of neurotoxic factors, such as inflammatory mediators, platelet-derived growth factor (PDGF),
nitrogen oxide, and quinolinic acid (QUIN). This leads to dysfunction and neuronal death [2,61].
A previous study has shown that despite effective antiretroviral treatment, cytokines such as CCL2,
IL-8, CCL3, CXCL10, IFN-γ, and IL-6 were expressed at higher levels in HIV-1 infected patients with
respect to uninfected ones. The higher expression of such cytokines indicates a continuous neuronal
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inflammation which in turn promotes HAND-associated encephalopathy [1]. Accordingly, Vera and his
group have also recently shown the presence of neuroinflammation markers in neuro-asymptomatic
HIV-infected patients (despite the effective control of viraemia) [62]. This status is probably related
to the impressive microbial translocation from the gut to the bloodstream, causing an extensive
inflammation and abnormalities in white matter integrity. These aspects could play an essential role in
the pathogenesis of HIV-associated neurocognitive disorders [63].
5. The Role of HIV-1 Proteins in HAND
The role of HIV in inducing neuronal damage is deeply described in several works [1,64–68]. Most
of these papers focused their attention on the role of the HIV-1 regulatory proteins in this phenomenon
(Table 2).
Table 2. The effects of viral regulatory proteins on HAND.
Regulatory Protein Effects on Hand
Tat
- Interacts with Cyclin T1 and CDK9 (69);
- Induces the expression of MCP-1/CCL2 (72);
- Induces the expression of IL-1β (73);
- Induces the expression of GFAP (74);
- Up-regulates the Cx43 human gene (75);
- Reduces GABA in the cortex (76);
- Modulates cellular gene expression;
- Increases the expression of GLUT1 in the cortex and hippocampus (76);
- Induces the expression of GAC (77);
- Reduces the expression of SYN (78);
- Increases leukocyte infiltration (72);
Gp120
- Stimulates the release of inflammatory cytokines and toxic substances
(79);
- Reduces the expression of beclin-1, LC3, and MAP2 (82);
- Stimulates the accumulation of β-APP (84);
Vpr
- Stimulates the release of TNF-α, IL-1β, and IL-8 in macrophages;
- Induces the release of neurotoxins (matrix metalloproteinases);
- Promotes cell-cycle and pro-apoptotic proteins (59);
Nef
- Increases the sensitivity of astrocytes to hydrogen peroxide (87);
- Promotes the astroglial activation and astrogliosis (88);
- Increases the apoptosis of MVEC (57);
6. Tat
In the pathogenesis of HIV-1 infection, a crucial role is played by the regulatory protein Tat [69,70].
Several studies demonstrated that Tat is able to contribute in a different way to neuronal damage.
In fact, the exposure of human astrocytoma cells to HIV-1 Tat recombinant protein had a higher level
of apoptosis compared to untreated cells [36]. In line with this, the injection at the cerebral level of Tat
in mice induces an increase of the Ca2+ v1.2 channels, inducing astrogliosis in the cortical region and
subsequent death of cortical neurons, microglia, and monocytes [71,72].
Tat seems to also have a role in promoting leukocyte infiltration and invasion [73]. Indeed, this
protein induces the expression of both cytokines and chemokines, such as MCP-1/CCL2 (Monocyte
chemoattractant protein type 1), of the protein family of CAM (V-CAM 1 and I-CAM1), and the
platelet-activating factor (PAF) production [73]. The HIV-1 Tat protein also induces the expression of
IL-1β mRNA in a dose-dependent manner [74]. A recent study has shown that Tat can also induce
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GFAP (glial fibrillary acidic protein) up-regulation, which is known to promote GFAP aggregation and
the induction of oxidative stress in astrocytes [75].
In recent findings, the HIV-1 Tat protein also shows a role in up-regulating the Cx43 human gene,
involved in the CNS gap junctional communication and promoting, if over-expressed, apoptosis and
inflammation, by binding the Cx43 promoter and thus increasing Cx43 mRNA production [76]. In vitro
and in vivo studies (based on transgenic mice) have shown that Tat induces a latency excitatory state
that may increase the neurotoxic and excitotoxic effects at the presynaptic level [77,78]. Tat may also
induce the loss of post-dendritic synapses due to the interference with glutamatergic signaling [79]
and with the expression of the dopamine transporter in both the striatum and midbrain [80,81].
7. Gp120
The envelope glycoprotein gp120, secreted from infected cells, is also involved in HIV-1
pathogenicity [82]. This protein indirectly induces neuronal damage, by stimulating the release
of inflammatory cytokines and toxic substances [80]. Moreover, this viral protein might alter
the expression of toll-like receptors (TLRs) on astrocytes, favouring the release of TNF-α, IL-6,
RANTES/CCL5, and reactive oxygen species, and thus affect the pathogenicity of HIV [82]. Several
studies have shown the involvement of gp120 in various processes, such as autophagy. By analysing
the markers of autophagy in the brain of gp120-expressing mice, Fields et al. observed a reduced
expression of beclin-1, LC3, and neuronal marker MAP2 [83]. In the II, III, and V layers of pyramidal
neurons of the midfrontal cortex, this catabolic process is reduced in aged patients compared to young
HIV+ and HIV Encephalopathy (HIVE) patients. This leads to the accumulation of altered proteins that
can damage the neuronal tissue [83]. In addition, rat cortical neuronal cultures, chronically treated with
gp120, showed an increased outward of K+ current in a dose-dependent manner [84]. At the neuronal
level, the K+ increase positively stimulates the apoptotic process. Furthermore, ex vivo studies on
the corpus callosum (CC) of HIV infected rats showed that gp120 can stimulate the accumulation of
β-APP (a β-amyloid precursor) in axons and induce damage, that can be limited or even stopped
with the treatment of CXCR4-antagonists [85]. Thus suggests that the interaction between gp120 and
CXCR4 can be important in gp120-mediated CNS damage.
8. Vpr
HIV-1 Vpr (Viral protein R) is an accessory protein that plays different roles during the virus
life cycle [86]. This viral protein is released from infected cells, but it can be incorporated in
both defective and complete viral particles [60]. This protein is known to increase the release of
pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-8 in macrophages, probably acting on the
MAPK pathway. It induces apoptosis, probably through the induction of IL1-β and IL-8, known to
induce the release of neurotoxins such as matrix metalloproteinases, and to promote cell-cycle and
pro-apoptotic proteins [60].
9. Nef
HIV-1 Nef is an important viral protein which promotes viral replication and infectivity, by
down regulating MHC I receptor expression [87]. In addition, this protein increases the sensibility
of astrocytes to hydrogen peroxide [88]. Moreover, this protein promotes astroglial activation and
astrogliosis [45]. Nef can also increase the permeabilization of lysosomes causing enzyme release [89],
and the subsequent apoptosis of vascular endothelial micro cells (MVECs) [58].
10. The Role of Co-Infections
Although the effect of HIV-1 in the CNS has been extensively studied, limited information is
available on the effect of co-infection in the CNS.
Epidemiological studies suggest that HIV/HCV co-infection is associated with an accelerated
progression of the HIV disease, worsened clinical outcomes, and increased mortality [90,91]. Moreover,
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individuals co-infected with HIV/HCV most frequently showed neuropsychological deficits, indicative
of cognitive disorders [92–94].
It has been shown that both viruses are able to increase the permeability of the BBB. In addition,
both HIV-1 and HCV have the ability to infect and replicate in microglia, inducing increased expression
of proinflammatory cytokines and chemokines, including IL-6 and IL-8.
Vivithanaporn and his group have also shown for the first time that the HCV core protein activates
human glia and contributes to neurotoxicity. The in vitro and in vivo aberrant immune activation
and neurotoxicity mediated by the HCV core protein were amplified in the presence of the HIV-1
Vpr protein [95]. The data obtained from this study suggest that in individuals co-infected with
HIV and HCV, the presence of HCV-proteins causes neuronal damage and perhaps neurocognitive
impairment [95].
Recently, Antinori et al. have shown that in HIV/HCV co-infected patients, the levels of HIV-RNA,
detectable in both plasma and cerebrospinal fluid (CSF), are associated with increased levels of
immunoactivation, neuroinflammation, and neuroinjury biomarkers. Furthermore, the presence of an
active HCV replication in CSF seems to be related to increased immunoactivation/inflammation and
neuronal injury [96].
Beyond HCV, Herpes Viruses 6, 7 (HHV-6 and HHV-7), and the JC virus (JCV) seem to have a
role in accelerating the progression of neurological diseases. For example, HHV-6 stimulates HIV-1
replication into the brain and exacerbates the neurological deficits in children [97]. This herpes virus
was also recently described as a causative agent of severe human encephalitis in a HIV-1 infected
patient [98]. In the same line of this report, in 2016 the first evidence of a correlation between HHV-7
reactivation and acute myelitis was published [99]. Regarding the polyomaviruses, JCV is known to
cause progressive multifocal leukoencephalopathy (PML) in HIV-1 infected individuals [100], resulting
from oligodendrocyte lytic infection. Recently, another polyomavirus, HPyV6, seems to have a primary
role in favoring demyelination in HIV-1 coinfection [101].
Greater attention has been paid in the last few years to the capacity of microbiomes to influence
neurocognitive disorders in HIV-1 infected patients. In particular, the gut microbiome has been
implicated in the development and function of brain circuits that support emotion and cognition. Thus,
specific modifications may impair this development. In line with this, Perez-Santiago and colleagues
showed that the genera of bacteroidetes and firmicutes are more frequently detected in patients with
the most severe form of HAND, the HAD, with respect to patients with ANI and MND [102].
11. Antiretroviral Therapy and HAND
Great progress has been made in antiretroviral therapy in the last few decades, with a significant
improvement in neurological clinical outcomes for HIV-1-infected patients. In particular, in order to
reduce the incidence of neurological complications associated with HIV-1 infection [103], international
guidelines recommend an immediate first-line treatment regimen for all new diagnosed infected
patients [104].
However, despite the efficacy of the current antiretroviral therapy in controlling HIV-1, viral
replication can still be found in the cerebrospinal fluid in some patients. Indeed, antiretrovirals
reach different areas of CSF with significant variability due to the different expression profiles of
cellular drug transporters, and the concentrations of some antiretrovirals do not exceed the inhibitory
concentration for wild-type HIV replication in CSF (Table 3) [105,106]. The suboptimal concentrations
of antiretrovirals within this site also represent the main limitation to achieving HIV-1 eradication from
the brain.
Several factors influence drug concentration in the brain tissue such as molecular weight,
lipophilicity, and blood’s protein binding [107–110]. For example, while entry and integrase
inhibitors are able to reach the CNS, the nucleoside/nucleotide reverse transcriptase inhibitors
and non-nucleoside reverse-transcriptase inhibitors can only partially cross the BBB. Conversely,
the majority of protease inhibitors (PI) are characterized by a medium/low permeability to the
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BBB [8,111–113]. Moreover, several cellular transporters (P-gp, MRP4, and MRP5) can reduce the
optimal intracellular concentration of antiretroviral drugs, thus favoring both the emergence of
drug-resistant viruses but also their productive infection to other cells [49,58,114,115].
Table 3. CNS penetration of the antiretroviral drugs
Drug Class Drug a CNS Penetration b
Entry/Fusion inhibitors ENF Low
MVC High
Integrase strand Transfer inhibitor RAL Medium
EVG Medium
Nucleoside Reverse Transcriptase inhibitor
ZDV High
3TC Medium
D4T Medium
DDI Medium
ABC Medium
TDF Low
FTC medium
Non-nucleoside Reverse Transcriptase inhibitor
EFV medium
NVP High
DLV High
ETR Low
Protease inhibitor
APV medium
IDV medium
DRV medium
RTV Low
LPV Medium
NFV Low
SQV Low
ATV Medium
FPV Medium
TPV Low
a ENF: Enfuvirtide; MVC: Maraviroc; RAL: Raltegravir; EVG: Elvitegravir; ZDV: Zidovudine; 3TC: Lamivudine;
D4T: Stavudine; DDI: Didanosine; ABC: Abacavir; TDF: Tenofovir Disoproxil Fumarate; FTC: Emtricitabine; EFV:
Efavirenz; NVP: Nevirapine; DLV: Delavirdine; ETR: Etravirine; APV: Amprenavir; IDV: Indinavir; DRV: Darunavir;
RTV: Ritonavir; LPV: Lopinavir; NFV: Nelfinavir; SQV: Saquinavir; ATV: Atazanavir; FPV: Fosamprenavir; TPV:
Tipranavir. b Data on Drug penetration were based on Ref. [111,114].
To increase the concentrations of antiretrovirals within this site, new strategies have been
identified. For example, the usage of a hypertonic solution of urea or mannitol [50,51] may inhibit drug
efflux transport, while nanoparticles and cell-mediated nanoART may confer other key advantages,
such as improved blood half-life and bioavailability, higher aqueous stability, and precise delivery [110].
In recent years, different types of nanoparticles have been identified. The most important are: (i) Lipid
Nanoparticles (liposomes and solid lipid nanoparticles), that easily cross the barrier due to their lipidic
nature [116,117]; (ii) Polymeric Nanoparticles, that exploit the interaction with low density lipoproteins
(LDL) receptors on the surface of endothelial cells [111,118]; (iii) Inorganic Nanoparticles, such as small
size silica with the addition of polyethylene glycol (PEG) [119], and Gold nanoparticles conjugated
with cell-penetrating peptides (CPP) [120].
Recently, several groups reported that poly (dl-lactide-co-glycolide) nanoparticles increase the
peak concentrations of ritonavir, lopinavir, and efavirenz, all drugs characterized by a low penetration
into the CNS. When loaded with Ritonavir, for example, these nanoparticles significantly improved the
trans-BBB delivery of the drug in mouse models, inhibiting viral replication in macrophages without
inducing neuronal-toxicity [121]. Fiandra and his group reported that poly (dl-lactide-co-glycolide)
nanoparticles also increase the peak concentrations of efavirenz [111]. In order to improve the PI
penetration into the CNS, two novel non-peptidic PIs, GRL-04810 and GRL-05010, have been also
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developed. Both these PI are characterized by two additional fluorine atoms that confer to the drugs
an increase ability to cross the BBB [8]. However, in order to confirm these findings and the potential
role of these compounds in clinical settings, further studies are needed.
In recent years, a CSF Penetration Effectiveness score (CPE) based on pharmacokinetics’
characteristics of various antiretroviral drugs was proposed in order to estimate the efficacy of
antiretroviral treatment in the CSF [106]. The effect of this CPE on clinical outcomes in HIV-1 infected
individuals was investigated by several papers that showed opposite results [122–124]. In particular,
while Marra and colleagues demonstrated poorer neurocognitive outcomes in patients with higher CPE
scores, other groups found an increased risk of developing dementia in the presence of antiretroviral
drugs characterized by good penetration [122–124]. These contrasting observations indicate that
further studies are required to safely prescribe ART and that regimens characterized by high CPE
scores should be carefully chosen in light of the fragile balance between the risk and benefit outcomes.
The acceleration of neurological disorders in the presence of high CPE observed in several clinical
studies should be also related to the neuronal toxicity induced by certain antiretroviral drugs, as
demonstrated in cell culture and macaques [125,126]. For example, PIs are shown to induce oxidative
stress in neuronal cells, while the NNRTI efavirenz caused toxicity in the cortical neuronal cultures of
foetal rats [125–127]. However, further in vivo studies are needed to confirm the neurotoxicity profiles
of these drugs for potential applications in clinical practice.
12. The Compartmentalization of HIV Infection in the CNS
Newly infected individuals typically have homogeneous HIV populations in their blood that
evolve during untreated infection to generate diverse viral variants. Compartment-specific selective
pressures can subsequently lead to the different evolution of HIV populations in different anatomical
sites during the course of infection, including in the CNS. The role of the CNS as an anatomical
compartment for HIV infection has been highlighted by several studies [128–130]. Harrington and
coworkers have elegantly investigated HIV-1 env compartmentalization between cerebrospinal fluid
and peripheral blood plasma over all stages of the HIV-1 disease course, including in patients with
neurological disorders [129]. Compartmentalization was found only in chronically infected patients
with neurological dysfunction, and in patients with HIV-associated dementia (HAD) [129]. This
suggests that HIV-1 adaptation and evolution in the CNS milieu play a pivotal role in the onset of
neuronal damage. Another interesting study has compared the kinetics of viral decay in cerebrospinal
fluid under therapy between asymptomatic patients and in patients with profound immune-depletion
and HAD [130]. The authors highlighted a slower viral decay in patients with HAD than in
asymptomatic patients; this was not associated with poorer CNS drug penetration, drug resistant
viruses in the cerebrospinal fluid, or to the differential presence of the CXCR4-using strains. They
proposed a model in which the absence of CD4+ T cells, consequent to profound immunodeficiency,
allows peripheral uninfected monocytes to massively migrate in the CNS, to differentiate into
perivascular macrophages, and to sustain high levels of HIV-1 replication, thus favouring the onset of
a genetically compartmentalized virus in the CNS.
In line with this model, the HIV-1 load in the CNS seems to be essential for the genesis of neuronal
damage [131]. In particular, Soulie and coworkers have found that the ratio of the HIV-1 load in
cerebrospinal fluid to the HIV-1 load in plasma is significantly higher in patients with HIV encephalitis
than in patients without neurological disorders (11.1 versus 0.7, p = 0.0006), proposing this ratio as an
instructive marker in predicting HIV encephalitis [131]. By these findings, compartmentalization
of HIV-RNA in the CNS has been frequently associated with greater inflammation and worse
neurocognitive outcomes.
As previously mentioned, ART has markedly reduced the incidence of HIV-associated dementia.
However, the true impact of early ART initiation on HIV-compartmentalization has been only recently
investigated. In fact, little is known about the HIV populations persisting in this anatomic compartment
during the earliest phase of HIV infection, and especially during suppressive ART. In this regard,
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a recent study showed that early antiretroviral treatment is associated with a smaller amount of
HIV-DNA and a lower molecular diversity of HIV-1 quasispecies in the CSF cells, compared to later
ART. Despite this correlation, most participants presented evidence of genetic compartmentalization
of the HIV-DNA quasispecies within the CSF with respect to the viral population in blood cells [132],
suggesting that early ART is not enough to limit HIV-1 evolution in this compartment. Nightingale
and his group have also shown that the discordance between CSF and plasma is more frequently
found in patients with low level viremia, and is associated with antiretroviral resistance mutations in
the CSF [133], suggesting differential emergence and selection of drug resistance mutations between
the CSF and blood during antiretroviral therapy failure, even if at a low viral load.
13. Conclusions
Since HIV is able to cross the blood-brain barrier, it can cause infection of the central nervous
system. The infection of this compartment involves different cell types but mostly macrophages, that
play a crucial role in the neurodegeneration process, releasing neurotoxins, inflammatory cytokines,
and viral proteins. Microbial translocation and HCV-coinfection can worsen this pathological condition.
However, the optimization of the delivery of antiretroviral drugs into the CNS by nanoformulations
has improved the control of HIV-associated neurocognitive disorders and has strongly limited HIV-1
replication. However, it is still insufficient per se to limit viral compartmentalization and to definitely
abolish viral residual replication into the CNS.
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